Systemic sclerosis & Raynaud's
COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study
Authors' conclusion
Most people with SSc in the study were fully vaccinated, and most continued their methotrexate or mycophenolate post-primary and booster vaccinations. Over half of vaccine-hesitant participants were concerned regarding risk of SSc flare; however, few vaccinated participants reported this.
Study context
- Population
- Adults with systemic sclerosis (SSc) in the SPIN Cohort489 with 2022 data
- Participants
- 1,033 adults
- Outcome
- Self-reported COVID-19 vaccination rates, including boosters
- Follow-up
- June-July 2022
Methodological detailssurvey, repeated surveys April-May 2021 and June-July 2022, self-reported
- Survey
- Repeated surveys April-May 2021 and June-July 2022
- Self-reported
Main finding
As reported in the abstract
Received both primary and booster vaccines (of 489)
437
89 %
Received at least one dose (of 1,033)
960
93 %
Observational data: associations, not effects.
Further findings
Peri-vaccination stop or decrease of MTX or mycophenolate
- First dose
- 34 of 266 (13 %)
- Second dose
- 32 of 215 (15 %)
- Booster
- 28 of 148 (19 %)
Worry about vaccine-related SSc flares among those not fully vaccinated (n=52) · 2022
- Reported worry
- 29 (56 %)
History of ≥1 COVID-19 infection (2022 participants)
- ≥1 infection
- 172 of 489 (35 %)
- After at least a primary vaccine series
- 114 (66 %)
Severity of initial COVID-19 infections
- Asymptomatic
- 9 (5 %)
- Mild
- 66 (38 %)
- Moderate
- 82 (48 %)
- Hospitalization
- 15 (9 %)
Safety
At least one adverse reaction (primarily sore arm and fatigue)
%
- After first dose: 330 of 960 participants
- 34
- After second dose: 314 of 657 participants
- 48
- After booster dose: 147 of 437 participants
- 34
- No severe adverse reactions were reported
SSc symptom worsening
%
- After first dose: 53 of 960
- 6
- After second dose: 39 of 657
- 6
- After booster dose: 17 of 437
- 4
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →